title: Escalation with overdose control using time to toxicity for cancer phase I clinical trials.
abstract: Escalation with overdose control (EWOC) is a Bayesian adaptive phase I clinical trial design that produces consistent sequences of doses while controlling the probability that patients are overdosed. However, this design does not take explicitly into account the time it takes for a patient to exhibit dose limiting toxicity (DLT) since the occurrence of DLT is ascertained within a predetermined window of time. Models to estimate the Maximum Tolerated Dose (MTD) that use the exact time when the DLT occurs are expected to be more precise than those where the variable of interest is categorized as presence or absence of DLT, given that information is lost in the process of categorization of the variable. We develop a class of parametric models for time to toxicity data in order to estimate the MTD efficiently, and present extensive simulations showing that the method has good design operating characteristics relative to the original EWOC and a version of time to event EWOC (TITE-EWOC) which allocates weights to account for the time it takes for a patient to exhibit DLT. The methodology is exemplified by a cancer phase I clinical trial we designed in order to estimate the MTD of Veliparib (ABT-888) in combination with fixed doses of gemcitabine and intensity modulated radiation therapy in patients with locally advanced, un-resectable pancreatic cancer.
authors.affiliation: Samuel Oschin Comprehensive Cancer Institute, Biostatistics and Bioinformatics Research Center, Los Angeles, California, United States of America.
authors.forename: Mourad
authors.initials: M
authors.lastname: Tighiouart
authors.affiliation: Winship Cancer Institute, Emory University, Atlanta, Georgia, United States of America.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Samuel Oschin Comprehensive Cancer Institute, Biostatistics and Bioinformatics Research Center, Los Angeles, California, United States of America.
authors.forename: André
authors.initials: A
authors.lastname: Rogatko
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017321:Clinical Trials, Phase I as Topic; D062787:Drug Overdose; D006801:Humans; D020714:Maximum Tolerated Dose; D008962:Models, Theoretical; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents